Results 31 to 40 of about 1,352 (137)

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

BMC Cardiovascular Disorders, 2022
Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis.
Ashutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, Mats Bergström, Swethajit Biswas, Chao Chen, Joseph Cheriyan, Matthew Cleveland, Louise Cookson, Paul Galette, Robert L. Janiczek, Raymond Y. Kwong, Mary Ann Lukas, Helen Millns, Duncan Richards, Ian Schneider, Scott D. Solomon, Jens Sörensen, James Storey, Douglas Thompson, Guus van Dongen, Danielle J. Vugts, Anders Wall, Gerhard Wikström, Rodney H. Falk   +24 more
doaj   +1 more source

A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies [PDF]

, 2012
BACKGROUND: We describe a new method for biodistribution studies with IRDye800CW fluorescent antibody probes. This method allows the quantification of the IRDye800CW fluorescent tracer in percentage of injected dose per gram of tissue (% ID/g), and it is
Bergen en Henegouwen, P.M. van, Cohen, R., Diest, P.J. van, Dongen, G.A.M.S. van, Elias, S.G., Mali, W., Oliveira, S., Walsum, M.S.   +7 more
core   +1 more source

A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging [PDF]

, 2021
In this work, we designed, developed, characterized, and investigated a new chelator and its bifunctional derivative for 89Zr labeling and PET-imaging. In a preliminary study, we synthesized two hexadentate chelators named AAZTHAS and AAZTHAG, based on
Calogero D’Alessandria, Francesco De Rose, Leone Loredana, Lisa Russelli, Markus Schwaiger, Sybille Reder, Tei Lorenzo   +6 more
core   +1 more source

Fluorine‐18‐Labeled Nucleotide Analogs Targeting Ecto‐5'‐Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors

Angewandte Chemie, Volume 138, Issue 17, 20 April 2026.
Fluorine‐18‐labeled CD73 inhibitor [18F]PSB‐19427 enables noninvasive PET mapping of CD73 overexpression in triple‐negative breast (TNBC) and pancreatic cancer. For [18F]PSB‐19427, specific binding in human tumor tissues, favorable biodistribution with prolonged blood retention, robust tumor uptake, and superiority to [18F]FDG in a TNBC model ...
Clemens Dobelmann, Constanze C. Schmies, Georg Wilhelm Rolshoven, Mirko Scortichini, Stefan Wagner, Andreas Isaak, Riham M. Idris, Jennifer Dabel, Lucie Grey, Karolina Losenkova, Susanne Moschütz, Haneen Al Hroub, Antje Keim, Sandra Höppner, Jouko Sandholm, Pia Boström, Maija Hollmén, Norbert Sträter, Sven Hermann, Gennady G. Yegutkin, Kenneth A. Jacobson, Sonja Schelhaas, Christa E. Müller, Anna Junker   +23 more
wiley   +2 more sources

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89. [PDF]

PLoS ONE, 2017
The development of bifunctional chelators (BFCs) for zirconium-89 immuno-PET applications is an area of active research. Herein we report the synthesis and evaluation of octadentate hydroxyisophthalamide ligands (1 and 2) as zirconium-89 chelators. While
Nikunj B Bhatt, Darpan N Pandya, Jide Xu, David Tatum, Darren Magda, Thaddeus J Wadas   +5 more
doaj   +1 more source

Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors

Frontiers in Oncology, 2023
IntroductionWe previously developed a 89Zr-labeled antibody-based immuno-positron emission tomography (immunoPET) tracer targeting interferon gamma (IFNγ), a cytokine produced predominantly by activated T and natural killer (NK) cells during pathogen ...
Justin B. Hackett, Nicholas Ramos, Stephen Barr, Madeline Bross, Nerissa T. Viola, Heather M. Gibson   +5 more
doaj   +1 more source

Analyzing of Production Conditions of 89Zr in the Particle Accelerator

Cumhuriyet Science Journal, 2019
Nowadays 89Zr is outstanding PET radionuclidewith its physical half-life (t1/2 ~ 78 hours), useful decay specifications andso that it is suitable for antibody-based immuno-PET.
Özge Kozguş Güldü, Perihan Ünak, Buğra Gökhun Bulduk, Volkan Tekin, Ayfer Yurt Kılçar   +4 more
doaj   +1 more source

Current Perspectives on (89)Zr-PET Imaging [PDF]

, 2020
(89)Zr is an emerging radionuclide that plays an essential role in immuno-positron emission tomography (PET) imaging. The long half-life of (89)Zr (t1/2 = 3.3 days) is favorable for evaluating the in vivo distribution of monoclonal antibodies.
An, YS, Lee, SJ, Park, BN, Ryu, EK, Yoon, JK   +4 more
core   +1 more source

Zirconium-89 labeled antibodies: general considerations towards radioisotope production and labelling strategies [PDF]

, 2023
Radiopharmaceutical preparations based on zirconium-89 ( 89Zr) radioisotope in the last decade have been increasingly used in preclinical and clinical studies for visualisation by positron emission tomography (PET).
Angelovska, Bistra, Atanasova, Marija, Cocevska, Maja, Janevik-Ivanovska, Emilija, Kolevska, Katerina, Ugrinska, Ana, Velickovska, Maja   +6 more
core  

A Reflection on the Evolution of Antibody-Based Therapies in Oncology: Trastuzumab as an Exemplar-Commentary on Dijkers et al. [PDF]

Clin Pharmacol Ther
Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1577-1587, June 2025.
Holstein SA.
europepmc   +2 more sources